Volumen: 18 # Number : 2
Publication Date : Mayo - Agosto Year: 2014
Romidepsin: an histona deacetylase inhibitor,
employed in the second line
of treatement of refractory/relapsed T cell lymphomas
Authors: Norma Tartas
Abstract: Romidepsin is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphomas. Phase II trials have shown activity of this drug in previously treated
patients with peripheral-Tcell lymphomas(PTCL)
About 29% of global responses and 19% of complete responses
were obtained, interestingly patients in complete remission after treatment with romidepsin, had a prolonged
disease free survival.
Phase III trials integrating romidepsin with other active drugs earlier in the treatment of the disease should be performed.
Key words: Romidepsin,
histona deacetylase inhibitor,
relapsed/refractory T-cell lymphomas
Pages : 156-158
|
